AIMM Therapeutics

2:30 PM - 2:45 PM, Tuesday, October 22, 2019 ・ 2nd Floor
AIMM is an antibody company which selects functional antibodies directly from cured cancer patients. We are advancing a lead compound into the clinic (Q4 2020) with the next clinical candidate to be designated in 2020.
Company Type:
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Netherlands
Year Founded:
2004
Main Therapeutic Focus:
Lead Product in Development:
AT1412
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO
AIMM Therapeutics